CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***].” CHINA CLINICAL TRIAL...Services Agreement • May 14th, 2024 • BioAtla, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 14th, 2024 Company IndustryThis China Clinical Trial Services Agreement (“Agreement”), made as of this 8th day of April 2022 (the “Effective Date”), is by and between BioAtla, Inc. (“BioAtla”), a Delaware corporation having a place of business at 11085 Torreyana Road, San Diego, CA 92121 and Himalaya Therapeutics Limited Company, a company organized under the laws of Shanghai, having a registered office 3rd Floor, Building 2, No. 200 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone (“Sponsor”). BioAtla and Sponsor are each referred to herein individually as a “Party” and collectively “Parties”.
RESTRICTED STOCK UNIT AGREEMENT UNDER THE BIOATLA, INC. 2020 EQUITY INCENTIVE PLANRestricted Stock Unit Agreement • May 14th, 2024 • BioAtla, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 14th, 2024 Company Industry JurisdictionTHIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) is between BioAtla, Inc., a Delaware corporation (the “Company”), and See Third-Party Administrative Platform (the “Grantee”) and is made as of See Third-Party Administrative Platform (the “Grant Date”).